• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

种间标度法在双吡啶肟HI-6中的应用。

Application of interspecies scaling to the bispyridinium oxime HI-6.

作者信息

Baggot J D

机构信息

Irish Equine Centre, Johnstown, Naas, County Kildare, Ireland.

出版信息

Am J Vet Res. 1994 May;55(5):689-91.

PMID:8067618
Abstract

Disposition kinetic variables of HI-6, a bispyridinium oxime, have been determined in mice, rats, rabbits, Rhesus monkeys, Beagles, sheep, and human beings. The drug has a short half-life, small apparent volume of distribution and high body clearance in these species, and is eliminated mainly by renal excretion. Using regression analysis and double logarithmic plots of the pharmacokinetic variables vs body weight of the various species, it was observed that body (systemic) clearance is the pharmacokinetic variable to use for interspecies comparison of elimination of the drug. The allometric exponent denoting the proportionality of body clearance of HI-6 to body weight of the 7 species studied was 0.76, which may be related to the renal excretion process for the drug. The apparent volume of distribution was similar (260 to 304 ml/kg of body weight) in the various species. The results indicate that volume of distribution, body clearance, and with less confidence, half-life might be used for interspecies scaling and for predicting these variables in other mammalian species. On the basis of the pharmacokinetic variables in selected species (rats and mice excluded), i.v. administration of HI-6 at a dosing rate of 20 to 25 mg/kg at 4-hour intervals should provide an average steady-state plasma concentration of 16 to 20 micrograms/ml in domestic animals. The short half-life of HI-6 precludes increasing the dosage interval.

摘要

双吡啶肟类药物HI-6在小鼠、大鼠、兔子、恒河猴、比格犬、绵羊和人类体内的处置动力学变量已被测定。在这些物种中,该药物半衰期短,表观分布容积小,机体清除率高,主要通过肾脏排泄消除。通过对药代动力学变量与各物种体重进行回归分析和双对数作图,发现机体(全身)清除率是用于药物消除种间比较的药代动力学变量。表示所研究的7个物种中HI-6的机体清除率与体重比例关系的异速生长指数为0.76,这可能与该药物的肾脏排泄过程有关。各物种的表观分布容积相似(260至304毫升/千克体重)。结果表明,分布容积、机体清除率,以及可信度稍低的半衰期,可用于种间标度和预测其他哺乳动物物种的这些变量。根据选定物种(排除大鼠和小鼠)的药代动力学变量,在家畜中以20至25毫克/千克的给药速率每隔4小时静脉注射HI-6,应可使血浆平均稳态浓度达到16至20微克/毫升。HI-6的半衰期短,因此无法延长给药间隔。

相似文献

1
Application of interspecies scaling to the bispyridinium oxime HI-6.种间标度法在双吡啶肟HI-6中的应用。
Am J Vet Res. 1994 May;55(5):689-91.
2
Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species.六种不同哺乳动物物种中香豆素药代动力学参数的种间缩放。
Methods Find Exp Clin Pharmacol. 1991 Dec;13(10):697-702.
3
Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
Am J Vet Res. 1999 Sep;60(9):1111-6.
4
Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.奥替普拉在小鼠、大鼠、家兔和犬体内的种间药代动力学尺度缩放及人体药代动力学预测。
Biopharm Drug Dispos. 2005 Apr;26(3):99-115. doi: 10.1002/bdd.437.
5
Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.新型勃起功能障碍治疗药物DA-8159在小鼠、大鼠、兔子和狗体内的种间药代动力学缩放以及人体药代动力学预测。
Biopharm Drug Dispos. 2005 Oct;26(7):269-77. doi: 10.1002/bdd.455.
6
Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans.肿瘤坏死因子受体-免疫球蛋白融合蛋白来那西普的动物药代动力学及其外推至人体的情况。
Drug Metab Dispos. 1999 Jan;27(1):21-5.
7
Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.地高辛特异性Fab片段清除率和分布容积的种间缩放
Toxicol Appl Pharmacol. 1996 May;138(1):84-9. doi: 10.1006/taap.1996.0101.
8
Pharmacokinetics and interspecies scaling of recombinant human factor VIII.重组人凝血因子VIII的药代动力学及种间缩放
Toxicol Appl Pharmacol. 1996 Jan;136(1):75-8. doi: 10.1006/taap.1996.0008.
9
Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?使用异速生长范式对单克隆抗表皮生长因子受体ior EGF/r3抗体处置进行种间缩放:它真的合适吗?
Biopharm Drug Dispos. 2004 May;25(4):177-86. doi: 10.1002/bdd.398.
10
Interspecies scaling of the pharmacokinetics of N-nitrosodimethylamine.N-亚硝基二甲胺药代动力学的种间缩放
Cancer Res. 1990 Jul 15;50(14):4366-70.

引用本文的文献

1
Allometric scaling of xenobiotic clearance: uncertainty versus universality.异生物清除的异速生长缩放:不确定性与普遍性
AAPS PharmSci. 2001;3(4):E29. doi: 10.1208/ps030429.
2
Scaling basic toxicokinetic parameters from rat to man.将大鼠的基本毒代动力学参数外推至人体。
Environ Health Perspect. 1996 Apr;104(4):400-7. doi: 10.1289/ehp.96104400.
3
Pharmacokinetics and molecular detoxication.药代动力学与分子解毒作用。
Environ Health Perspect. 1996 Mar;104 Suppl 1(Suppl 1):23-40. doi: 10.1289/ehp.96104s123.